Bosnian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

pancreatic neoplasms/edema

Veza se sprema u međuspremnik
Page 1 od 72 rezultati

[A case of pancreatic cancer complicated by gemcitabine-induced peripheral edema].

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Gemcitabine mono-therapy was carried out in an unresectable pancreatic cancer. After six courses of treatment, pitting edema appeared and gradually became worse especially after gemcitabine infusion. Gemcitabine-induced edema was suspected after exclusion of other causes. Diuretics and steroids were

[Anasarca, a complication of chemotherapy with gemcitabine in two patients with pancreatic cancer].

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Pancreatic adenocarcinoma is the fifth most common cause of cancer-related mortality in the world. The nucleoside analogue gemcitabine is the established standard therapy for advanced disease. Rare cases of gemcitabine-associated systemic capillary leak syndrome have been reported. Here, we present

Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
BACKGROUND Single agent gemcitabine (GEM) is the standard treatment of pancreatic adenocarcinoma. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor. Recent studies in human pancreatic tumor cell lines suggest an involvement of COX-2 in tumor-dependent angiogenesis and provide the rational

Secondary Minimal Change Disease Due to Pancreatic Cancer Improved by Chemotherapy

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
We herein describe an 82-year-old patient who presented with proteinuria and systemic edema. He was diagnosed with minimal change disease (MCD) and was found to have stage III pancreatic cancer. He could not undergo surgical resection due to invasion to the celiac artery and he was thus treated with

Dexamethasone intravitreal implant in cystoid macular edema secondary to paclitaxel therapy.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
To report the first case of cystoid macular edema (CME) induced by nabpaclitaxel treated with intravitreal dexamethasone implant.A 67 year-old man diagnosed with unresectable pancreatic cancer presented with decreased vision in both eyes while receiving

Erlotinib-induced episcleritis in a patient with pancreatic cancer.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
BACKGROUND Erlotinib is a relatively new anilinoquinazoline indicated for treatment of pancreatic cancer in combination with gemcitabine. It is a tyrosine kinase inhibitor that specifically targets epidermal growth factor receptor (EGFR), which is commonly overexpressed and/or mutated in solid
We report a case of pseudocirrhosis arising in the setting of regression of liver metastases from pancreatic cancer. A 55-year-old asymptomatic woman presented to our clinic with newly diagnosed metastatic pancreatic cancer with extensive liver metastases. She underwent systemic chemotherapy with

Severe cholestatic liver failure associated with gemcitabine adjuvant monotherapy for pancreatic cancer.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
We report a case of severe hepatic failure caused by gemcitabine hydrochloride (GEM) monotherapy after pancreaticoduodenectomy for advanced pancreatic cancer. A 73-year-old woman received GEM as an adjuvant chemotherapy. She suffered from progressive edema, fatigue, and jaundice after the third GEM
Background: Laparoscopic pancreaticoduodenectomy (LPD) technique with artificial vascular graft reconstruction for patients with borderline resectable pancreatic cancer has been rarely reported since it is a very challenging technique.

A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
OBJECTIVE The aim of the study was to assess the clinical efficacy and toxicity of single-agent imatinib mesylate in patients with advanced, unresectable metastatic pancreatic cancer. METHODS Previously treated or untreated patients with histologically proven, unresectable pancreatic adenocarcinoma

Gemcitabine-induced pleuropericardial effusion in a patient with pancreatic cancer.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
Pleuropericardial effusion is an extremely rare complication of gemcitabine chemotherapy. The patient was a 56-year-old woman administered systemic chemotherapy with gemcitabine for local recurrence of pancreatic cancer and lymph node metastasis developing 4 years after pancreaticoduodenectomy. Four
Pancreatic adenocarcinoma is one of the leading causes of cancer deaths in Japan. Erlotinib plus gemcitabine( GEM) combination therapy provided significant improvements in the overall and progression-free survival in a phase III trial in Canada and a phase II trial in Japan. As a result, this
Background: Although decongestive physiotherapy combined with diuretics may be efficient in limb edemas, no such therapy has been described in the context of anasarca. Case Description: A bedbound 62-year-old man with stage IV pancreatic cancer, presenting with progressing severe

Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
OBJECTIVE To date, no standard regimen for salvage chemotherapy after gemcitabine (Gem) failure has been defined for patients with advanced pancreatic cancer (PC). Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in PC patients. METHODS Within a prospective

[A Case of Cystoid Macular Edema Secondary to Albumin-Bound Paclitaxel Therapy].

Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
A 73-year-old woman diagnosed with unresectable pancreatic cancer received weekly gemcitabine(GEM)plus albuminbound paclitaxel(nab-PTX)therapy. Four months after nab-PTX therapy was initiated, she presented with a rapidly decreasing vision in her left eye at an ophthalmology clinic. On admission,
Pridružite se našoj
facebook stranici

Najkompletnija baza ljekovitog bilja potpomognuta naukom

  • Radi na 55 jezika
  • Biljni lijekovi potpomognuti naukom
  • Prepoznavanje biljaka po slici
  • Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
  • Pročitajte naučne publikacije povezane sa vašom pretragom
  • Pretražite ljekovito bilje po učincima
  • Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima

Google Play badgeApp Store badge